1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$85.67bn
- HK$90.92bn
- CNY31.83bn
Brief: Sino Biopharmaceutical Says Marketing Application For M701 Accepted By China In May 2026
Brief: Sino Biopharmaceutical Says Zongertinib Approved By NMPA China
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment (updated)
HK-listed Sino Biopharmaceutical hits 2-week high on GSK tie-up
GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
Brief: Sino Biopharmaceutical Says China CDE Accepts New Drug Application For M701 CD3/Epcam Bispecific Antibody
Brief: Sino Biopharmaceutical's Culmerciclib Capsule Receives NMPA Approval For First-Line Hr+/Her2- Advanced Breast Cancer In China
Brief: Sino Biopharmaceutical Says Benmelstobart, Anlotinib Receive NMPA Approval For Advanced ASPS In China
Brief: Sino Biopharmaceutical Says Naldemedine Approved For Marketing In Greater Bay Area
Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 "Pan-Kras Inhibitor" Approved By FDA
Brief: Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment
Brief: Sino Biopharmaceutical Reports Positive Results On Phase III Clinical Study Of TQB3454 IDH1 Inhibitor
Brief: Sino Biopharmaceutical Says TQB3205 Pan-Kras Inhibitor Receives NMPA Clinical Trial Approval
Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Brief: Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
Brief: Sino Biopharmaceutical Receives NMPA Approval For Rovadicitinib Tablet
Brief: Sino Biopharmaceutical Says NMPA Approved Benmelstobart Injection For Marketing
Sino Biopharmaceutical rises on progress of breast cancer drug